{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:01:14Z","timestamp":1782831674032,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with primary adrenal insufficiency need lifelong replacement therapy with glucocorticoids and mineralocorticoids, which may influence their bone quality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of the study was to evaluate densitometry parameters, trabecular bone score and sclerostin concentrations in patients with primary adrenal insufficiency in comparison to control group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We included 29 patients (62% females) with diagnose of autoimmune primary adrenal insufficiency (mean age 49.7 \u00b1 11.7 years, mean duration of the disease 13.2\u00b1 13.6 years) and 33 healthy subjects (adjusted with age, sex and body mass index). Bone mineral density at the femoral neck, lumbar spine, total body and trabecular bone score were evaluated. Serum sclerostin concentrations were measured.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no significant differences in densitometry parameters (T-score, Z-score, bone mineral density in all locations) as well as in trabecular bone score in patients with adrenal insufficiency in comparison to control group. Mean serum sclerostin concentration was significantly higher in patients with adrenal insufficiency than in control group (44.7 \u00b1 23.5 vs 30.7 \u00b1 10.4 pmol\/l, p=0.006). There was a negative correlation between trabecular bone score and the duration of adrenal insufficiency and age, also a negative correlation between femoral neck and total densitometry parameters and 24-hour urine cortisol as a marker of hydrocortisone daily dose in patients with adrenal insufficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The bone status in patients with primary adrenal insufficiency was not impaired in comparison to control group, while sclerostin concentration was higher. The duration of the disease and higher hydrocortisone doses may affect negatively bone status.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.996157","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T05:52:01Z","timestamp":1667368321000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Trabecular bone score and sclerostin concentrations in patients with primary adrenal insufficiency"],"prefix":"10.3389","volume":"13","author":[{"given":"Aleksandra","family":"Zdrojowy-We\u0142na","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jowita","family":"Halupczok-\u017by\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"S\u0142oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Syrycka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Gojny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Bolanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.5.5677-7","article-title":"Is the prevalence of addison\u2019s disease underestimated","volume":"84","author":"Laureti","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.t01-1-01552.x","article-title":"High prevalence and increasing incidence of addison\u2019s disease in western Norway","volume":"56","author":"L\u00f8v\u00e5s","year":"2002","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0756","article-title":"Increasing prevalence of addison\u2019s disease in German females: health insurance data 2008\u20132012","volume":"170","author":"Meyer","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01466.x","article-title":"Subjective health status in Norwegian patients with addison\u2019s disease","volume":"56","author":"L\u00f8v\u00e5s","year":"2002","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1331766","article-title":"What affects the quality of life in autoimmune addison\u2019s disease","volume":"45","author":"Meyer","year":"2013","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0685","article-title":"Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis","volume":"92","author":"Hahner","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0076","article-title":"Premature mortality in patients with addison\u2019s disease: a population-based study","volume":"91","author":"Bergthorsdottir","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0550","article-title":"Normal overall mortality rate in addison\u2019s disease, but young patients are at risk of premature death","volume":"160","author":"Erichsen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2265.2008.03340.x","article-title":"Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency","volume":"69","author":"Bensing","year":"2008","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2522","article-title":"Clinical and immunological characteristics of autoimmune Addison disease: A nationwide Swedish multicenter study","volume":"102","author":"Dalin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01324","article-title":"Visceral fat and novel biomarkers of cardiovascular disease in patients with addison\u2019s disease: A case-control study","volume":"102","author":"Bergthorsdottir","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1530\/EJE-08-0880","article-title":"Glucocorticoid replacement therapy and pharmacogenetics in addison\u2019s disease: effects on bone","volume":"160","author":"L\u00f8v\u00e5s","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02352.x","article-title":"Risk of hip fracture in addison\u2019s disease: a population-based cohort study","volume":"270","author":"Bj\u00f6rnsdottir","year":"2011","journal-title":"J Intern Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02473.x","article-title":"Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs","volume":"64","author":"Arlt","year":"2006","journal-title":"timed serum cortisol measurements. Clin Endocrinol (Oxf)."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01761.x","article-title":"Long-term follow-up of bone mineral density in addison\u2019s disease","volume":"58","author":"J\u00f3dar","year":"2003","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1210\/jcem-72-1-39","article-title":"Daily cortisol production rate in man determined by stable isotope dilution\/mass spectrometry","volume":"72","author":"Esteban","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and bone: Consequences of endogenous and exogenous excess and replacement therapy","volume":"39","author":"Hardy","year":"2018","journal-title":"Endocr Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25399","article-title":"Glucocorticoids hijack Runx2 to stimulate Wif1 for suppression of osteoblast growth and differentiation","volume":"232","author":"Morimoto","year":"2017","journal-title":"J Cell Physiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.01.117","article-title":"Glucocorticoid suppresses the canonical wnt signal in cultured human osteoblasts","volume":"329","author":"Ohnaka","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2869","article-title":"Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost\/Sclerostin","volume":"31","author":"Sato","year":"2016","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3308-6","article-title":"Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength","volume":"27","author":"Yao","year":"2016","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.08.016","article-title":"Effect of glucocorticoid treatment on wnt signalling antagonists (sclerostin and dkk-1) and their relationship with bone turnover","volume":"57","author":"Gifre","year":"2013","journal-title":"Bone"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2218","article-title":"Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment","volume":"97","author":"van Lierop","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10341","article-title":"Short-term glucocorticoid treatment reduces circulating sclerostin concentrations in healthy young men: A randomized, placebo-controlled, double-blind study","volume":"4","author":"Jacobsson","year":"2020","journal-title":"JBMR Plus"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0263","article-title":"Effect of adrenocorticotropic hormone infusion on circulating sclerostin levels","volume":"10","author":"Zaheer","year":"2021","journal-title":"Endocr Connect."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2017.06.006","article-title":"Older age and higher body mass index are associated with a more degraded trabecular bone score compared to bone mineral density","volume":"22","author":"Shin","year":"2019","journal-title":"J Clin Densitom."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.39726","article-title":"Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide: Trabecular bone score in glucocorticoid-induced osteoporosis","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.593173","article-title":"Decreased trabecular bone score in patients with active endogenous cushing\u2019s syndrome","volume":"11","author":"Stachowska","year":"2020","journal-title":"Front Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1134","article-title":"Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial","volume":"93","author":"Gurnell","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: An endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bone.2016.12.016","article-title":"Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T- and z-score, and reference databases","volume":"104","author":"Dimai","year":"2017","journal-title":"Bone"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2384-8","article-title":"Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women","volume":"24","author":"Dufour","year":"2013","journal-title":"Osteoporos Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1380-8","article-title":"Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with addison\u2019s disease on glucocorticoid and mineralocorticoid replacement therapy","volume":"59","author":"Camozzi","year":"2018","journal-title":"Endocrine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02320.x","article-title":"Why is the management of glucocorticoid deficiency still controversial: a review of the literature","volume":"63","author":"Crown","year":"2005","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13267","article-title":"Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity - data from the EU-AIR","volume":"86","author":"Murray","year":"2017","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa862","article-title":"Improved urinary cortisol metabolome in Addison disease: A prospective trial of dual-release hydrocortisone","volume":"106","author":"Espiard","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2017.06.019","article-title":"Use of trabecular bone score (TBS) as a complementary approach to dual-energy X-ray absorptiometry (DXA) for fracture risk assessment in clinical practice","volume":"20","author":"Shevroja","year":"2017","journal-title":"J Clin Densitom."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: A noninvasive analytical method based upon the DXA image: TRABECULAR BONE SCORE","volume":"29","author":"Silva","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/boneres.2017.13","article-title":"Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice","volume":"5","author":"Beier","year":"2017","journal-title":"Bone Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6614-5-14","article-title":"Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels","volume":"5","author":"Skowro\u0144ska-J\u00f3\u017awiak","year":"2012","journal-title":"Thyroid Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5937\/jomb0-24943","article-title":"The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction","volume":"39","author":"Mihaljevi\u0107","year":"2020","journal-title":"J Med Biochem"},{"key":"B43","doi-asserted-by":"publisher","first-page":"330ra35","DOI":"10.1126\/scitranslmed.aac4351","article-title":"Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction","volume":"8","author":"Wehmeyer","year":"2016","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.996157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T05:52:05Z","timestamp":1667368325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.996157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":43,"alternative-id":["10.3389\/fendo.2022.996157"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.996157","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"article-number":"996157"}}